Ask AI

Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies

Deepen your understanding of ADH1 as a cause of hypoparathyroidism, gain strategies for employing genetic testing to detect ADH1, and learn about the emerging role of calcium-sensing receptor–targeted therapies through expert-written ClinicalThought commentaries, downloadable slides, and an on-demand webcast.

Share

Program Content

Events

Activities

ADH1 Detection and Targeted Therapy
ADH1 in Hypoparathyroidism: Detection and CaSR-Targeted Therapies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with HypoPARAthyroidism Association, Inc.

Supporters

This activity is supported by an independent educational grant from BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

Partners

HypoPARAthyroidism Association, Inc

ProCE Banner